Clinical context
In glaucoma, intraocular pressure reduction is important but remains a surrogate outcome. Clinical value also depends on preservation of the visual field and optic nerve, safety, the need for additional medication or surgery, and treatment adherence. Target pressure is individualized, so the same numerical change can carry different meaning at different disease stages and rates of progression.
What was studied
Of 100 screened patients with primary angle-closure glaucoma and cataract, 66 were randomized to phacoemulsification with endoscopic cyclophotocoagulation or phacoemulsification alone and followed for 24 months. Baseline pressure was similar at 19.9 ± 5.8 and 19.5 ± 7.2 mmHg. Outcomes included pressure, medication use, angle opening, visual function, endothelial count, pupil diameter, success and complications.
How the evidence was produced
Randomization reduces the influence of known and unknown confounders and makes comparisons between interventions more reliable. Readers should still examine sequence generation, allocation concealment, masking of outcome assessors, the prespecified primary endpoint, losses to follow-up and intention-to-treat analysis. These details determine how confidently an observed difference can be attributed to the intervention.
How to interpret the result
Adding ECP produced a modest additional reduction in pressure and medication burden in selected eyes. The largest separation appeared at the strict 12-mmHg threshold, but this does not establish that the procedure replaces filtration surgery. Decisions should consider target pressure, optic-nerve damage, synechiae, prior iridotomy, medication burden and risks of inflammation or hypotony.
The result should be understood as an estimate for the population studied, not a promise of an individual outcome. Statistical and clinical significance, absolute and relative effects, and prespecified and exploratory analyses should be distinguished. When several endpoints or subgroups are reported, the prespecified primary endpoint for which the study was designed usually provides the most reliable inference.
Clinical applicability
The findings can inform discussions about treatment sequence and burden. Before changing management, compare the study population with the patient in front of you, including glaucoma stage, baseline pressure, previous treatment, angle anatomy and rate of field loss. A pressure measurement does not replace structural and functional follow-up.
Limitations
The sample included only 66 patients and appears to represent experience from one center. Two years allows an early comparison but is short for visual-field preservation and later surgery. The study did not show a significant difference in the uncommon trabeculectomy outcome and may have been underpowered for complications. The full paper should be checked for sequence generation, allocation concealment, masked assessment, attrition at 24 months, the ECP protocol, baseline glaucoma severity and definitions of complete and qualified success.
Beyond the limitations acknowledged by the authors, confidence is affected by sample size, follow-up duration, missing data, choice of comparator and relevance of the outcomes to routine care. Uncommon complications may remain undetected even in a well-conducted study. External validity is reduced when participants, equipment or investigator expertise differ substantially from everyday settings.
What to verify in the source
In the full paper, verify the protocol, eligibility criteria, baseline group characteristics, primary endpoint definition, confidence intervals, adverse events and losses to follow-up. Funding, conflicts of interest, trial registration and consistency between the published analysis and the original plan deserve separate attention. The DOI or source link below provides access to the primary publication for this check.